Tert-butyl-[4-(2-cyclopropylethynoxy)-3-ethyl-6-fluoroquinolin-2-yl]oxy-dimethylsilane | 777096-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Tert-butyl-[4-(2-cyclopropylethynoxy)-3-ethyl-6-fluoroquinolin-2-yl]oxy-dimethylsilane
• CAS: 777096-90-9
• 化学式: C₂₂H₂₈FNO₂Si
• 分子量: 385.554
• InChiKey: ZLDWCPGWCOPGEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.07
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Tert-butyl-[4-(2-cyclopropylethynoxy)-3-ethyl-6-fluoroquinolin-2-yl]oxy-dimethylsilane 在 acidic resin AG 50W-X₄ 作用下， 以 四氢呋喃 为溶剂， 以18 mg的产率得到4-[(2-Cyclopropylethynyl)oxy]-3-ethyl-6-fluoro-2(1H)-quinolinone
  参考文献：
  名称：

  Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.

  摘要：

  HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.

  DOI：

  10.1021/jm040072r
• 作为产物：
  描述：

  ethyl 2-(chlorocarbonyl)butanoate 在 甲烷磺酸 、 phosphorus pentoxide 、 lithium 、 sodium hydride 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 Tert-butyl-[4-(2-cyclopropylethynoxy)-3-ethyl-6-fluoroquinolin-2-yl]oxy-dimethylsilane
  参考文献：
  名称：

  Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.

  摘要：

  HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.

  DOI：

  10.1021/jm040072r